Physician profile
Mark E Mckenzie
NPI 1285659243
$950.19
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $123 · 2021: $214 · 2022: $259 · 2023: $216 · 2024: $138.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $354.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $353.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $214.54 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $212.99 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $103.50 | 2019-2022 | |
| Novo Nordisk INC | $91.91 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $51.80 | 2022-2023 | Gvoke Hypopen |
| Abbott Laboratories | $42.65 | 2023-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Abbvie INC. | $36.53 | 2022 | |
| Philips North America LLC | $31.11 | 2019 | |
| Grifols USA, LLC | $28.49 | 2023 | Prolastin-C Liquid |
| Allergan, INC. | $25.65 | 2019 | |
| Horizon Therapeutics Plc | $24.53 | 2023 | Krystexxa |
| Mylan Specialty L.P. | $22.24 | 2019 | |
| Dexcom, INC. | $19.58 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $16.05 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $14.89 | 2023 | Farxiga |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $13.73 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Mckenzie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.